Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting

Published: Apr 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large, late-stage human study, called ESTABLISH 2, and multiple other clinical studies from its experimental antibiotic, tedizolid phosphate (TR-701), will be presented in poster and oral presentations at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Berlin from April 27-30. A total of three tedizolid-related posters and one oral presentation have been accepted for presentation, including clinical and safety results.

Help employers find you! Check out all the jobs and post your resume.

Back to news